HARP News and Press, Harpoon Therapeutics Inc. From 05/28/21

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Iterum jumps even as RBC says sulopenem may not be a “shoo-in”Iterum Therapeutics (ITRM) is extending the post-market gains with a ~18.7% rise in early hours in reaction to the FDA decision not to hold an AdCom meeting for the company’s marketing application for...

SOUTH SAN FRANCISCO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that updated interim Phase 1 data for HPN424 for prostate cancer will be presented at ...

Harpoon Therapeutics (HARP): Q1 GAAP EPS of -$1.95 misses by $1.50.Revenue of $9M (+172.7% Y/Y) beats by $2.39M.Press Release For further details see: Harpoon Therapeutics EPS misses by $1.50, beats on revenue

Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs Appointed experienced biotech leader A lan Colowick, M.D., to board of directors Clinical data updates for a ...

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate i...

SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the availability of three poster presentations at the American Association for Cance...

An update on the 20 life sciences companies Numenor Capital has profiled so far range from cell therapy companies like SQZ Biotech and Orchard Therapeutics to biologics platforms like Pandion. The best performing investment, over 170% return, so far has been Pandion Therapeutics that ...

Harpoon Therapeutics is a platform immunotherapy company using its TriTAC technology to develop more stable bispecifics to treat cancer. The company has several catalysts for its pipeline of four clinical assets this year that can validate the TriTAC platform. Ultimately, Harpoon ...

SOUTH SAN FRANCISCO, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Alan Colowick, M.D., to its board of directors. Dr. Colowick is a...